Another Milestone for Vivesto’s Paccal Vet: Limited Market Classification in the EU for Canine Splenic Hemangiosarcoma
This classification may allow faster regulatory approval in the EU and protect Paccal Vet from generic competition for 10 years.
top of page
Apr 29
What's New With Canine Hemangiosarcoma?
The CCA webinar highlighted latest updates: promising treatments, clinical research insights, and World Veterinarian Cancer Congress
Mar 7
Paccal Vet Vaccine Administers Its First Dose, Signaling Hope for Canine Hemangiosarcoma Treatment
Vivesto AB explores the potential of a renowned anti-cancer drug, already successful in diverse canine cancers.
Feb 10
A New Vaccine To Prevent Eight Types of Cancer Is Close to Enter the Market
One step closer to a preventive lifesaving tool for our dogs
bottom of page